The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.

@article{Berk2014TheEO,
  title={The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial.},
  author={Michael Berk and Olivia M Dean and Sue M. Cotton and Sue Jeavons and Michelle Tanious and Kristy Kohlmann and Karen Hewitt and Kirsteen Moss and Christine Allwang and Ian Schapkaitz and Jenny Robbins and Heidi Cobb and Felicity Ng and Seetal Dodd and Ashley I. Bush and Gin S. Malhi},
  journal={The Journal of clinical psychiatry},
  year={2014},
  volume={75 6},
  pages={
          628-36
        }
}
OBJECTIVE Major depressive disorder (MDD) is one of the most common psychiatric disorders, conferring considerable individual, family, and community burden. To date, treatments for MDD have been derived from the monoamine hypothesis, and there is a paucity of emerging antidepressants, especially with novel mechanisms of action and treatment targets. N-acetylcysteine (NAC) is a redox-active glutathione precursor that decreases inflammatory cytokines, modulates glutamate, promotes neurogenesis… Expand
University of Groningen N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity
Background: A subgroup of depressed patients with increased inflammatory activity was shown to be more susceptible to develop Treatment Resistant Depression (TRD). Earlier studies withExpand
N-acetylcysteine (NAC) as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double- blind randomized placebo-controlled trial
Background: A subgroup of depressed patients with increased inflammatory activity was shown to be more susceptible to develop Treatment Resistant Depression (TRD). Earlier studies withExpand
N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial
TLDR
This is the first clinical trial taking both TRD and increased inflammatory activity as inclusion criteria, and will provide reliable evidence for the efficacy of NAC in patients with TRD displaying increasedinflammatory activity. Expand
N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence
TLDR
Current evidence supports N-acetylcysteine use as an adjunctive therapy clinically for psychiatric conditions, administered concomitantly with existing medications, with a recommended dosage between 2000 and 2400 mg/day. Expand
N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects
TLDR
Preliminary positive results were found in trials testing the use of NAC, mainly as an add-on treatment, in cannabis use disorder in young people, depression in bipolar disorder, negative symptoms in schizophrenia, and excoriation (skin-picking) disorder. Expand
Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor
TLDR
The results failed to support the hypothesis that IL6, CRP and BDNF are directly involved in the therapeutic mechanism of NAC in depression, but IL6 may be a useful marker for future exploration of treatment response. Expand
N‐acetylcysteine as a new prominent approach for treating psychiatric disorders
TLDR
Current knowledge on the ability of NAC to ameliorate symptoms and neuropathologies related to different psychiatric disorders, including attention deficit hyperactivity disorder, anxiety, bipolar disorder, depression, obsessive–compulsive disorder, obsessive-compulsive‐related disorder, posttraumatic stress disorder, and schizophrenia are summarized. Expand
Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
N-acetylcysteine (NAC) is recognized for its role in acetaminophen overdose and as a mucolytic. Over the past decade, there has been growing evidence for the use of NAC in treating psychiatric andExpand
Vitamin D and N-Acetyl cysteine supplementation in treatment resistant depressive disorder patients: a general review.
TLDR
This paper reviews the therapeutic use of Vitamin D and NAC and among individuals with refractory MDD to the first- line pharmacological interventions, reviewing the clinical studies published in the last decade. Expand
N-acetylcysteine for therapy-resistant tobacco use disorder: a pilot study
TLDR
Data show that treatment with NAC combined with appropriate psychotherapy appears to be an efficient treatment option for TUD. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial.
TLDR
These open label data demonstrate a robust decrement in depression scores with NAC treatment, and large placebo controlled trials of acute bipolar depression are warranted. Expand
N-acetylcysteine for major depressive episodes in bipolar disorder.
TLDR
It is indicated that adjunctive NAC may be useful for major depressive episodes in bipolar disorder and further studies designed to confirm this hypothesis are necessary. Expand
N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorder—A Double-Blind Randomized Placebo-Controlled Trial
TLDR
NAC appears a safe and effective augmentation strategy for depressive symptoms in bipolar disorder. Expand
The promise of N-acetylcysteine in neuropsychiatry.
TLDR
The efficacy pattern of NAC interestingly shows little respect for the current diagnostic systems, and its benign tolerability profile, its action on multiple operative pathways, and the emergence of positive trial data make it one of the most promising drug candidates in neuropsychiatric disorders. Expand
N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial.
TLDR
The effects of this compound in a subset of patients with bipolar II disorder from a randomized placebo-controlled trial could serve as a hypothesis-generating stimulus for further clinical trials of pharmacologic treatment for bipolar II depression. Expand
Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial
TLDR
There were no significant between-group differences in recurrence or symptomatic outcomes during the maintenance phase of the trial; however, these findings may be confounded by limitations. Expand
A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania
TLDR
Although the sample size was small, these results indicated within-group efficacy for this glutathione precursor as compared to placebo, and future trials specifically designed to demonstrate the efficacy of NAC in mania are needed. Expand
N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.
TLDR
N-acetylcysteine has shown promising results in populations with these disorders, including those in whom treatment efficacy has previously been limited, and the therapeutic potential of this acetylated amino acid is beginning to emerge in the field of psychiatric research. Expand
A Randomized Controlled Pilot Trial of Oral N-Acetylcysteine in Children with Autism
TLDR
Data from this pilot investigation support the potential usefulness of NAC for treating irritability in children with autistic disorder and large randomized controlled investigations are warranted. Expand
N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
TLDR
This trial suggests that N-acetylcysteine may be a safe and effective option to augment standard treatment in patients with refractory obsessive-compulsive disorder. Expand
...
1
2
3
4
5
...